The Food and Drug Administration (FDA) announces that Olympus has issued new, validated manual reprocessing instructions for the TJF-Q180V duodenoscope to replace those provided in the original labeling. The FDA has reviewed these new reprocessing instructions and the validation data as part of its ongoing review of the 510(k), and recommends that any facilities that are using Olympus’ TJF-Q180V duodenoscope train staff on the new instructions and implement them as soon as possible.
As noted in FDA’s February 2015 Safety Communication, the complex design of ERCP endoscopes (also called duodenoscopes) may impede effective reprocessing. Reprocessing is a detailed, multistep process to clean and disinfect or sterilize reusable devices. Recent medical publications and adverse event reports associate multidrug-resistant bacterial infections in patients who have undergone ERCP with reprocessed duodenoscopes, even when manufacturer reprocessing instructions are followed correctly. FDA has been working with duodenoscope manufacturers as they modify and validate their reprocessing instructions to further enhance the safety margin of their devices and show with a high degree of assurance that their reprocessing instructions, when followed correctly, effectively clean and disinfect the duodenoscopes.
In September 2014, Olympus initiated testing to validate new reprocessing instructions. The cleaning validation reports were provided to FDA in October 2014. While FDA found Olympus’ cleaning validation data acceptable, initial high level disinfection reports did not demonstrate an adequate safety margin, and so Olympus conducted additional testing. At the end of February 2015, Olympus submitted new high level disinfection validation data to FDA. The agency has reviewed this data and believes that, when followed, the new, validated reprocessing instructions for the Olympus TJF-Q180V duodenoscope are robust, and demonstrate consistent and reliable cleaning and high-level disinfection. At FDA’s request, Olympus has issued the new, validated instructions for reprocessing the TJF-Q180V duodenoscope.
To validate reprocessing instructions for duodenoscopes, manufacturers should soil their device with bacteria to simulate use in a procedure and then demonstrate that the device can be adequately disinfected through a sufficient reduction in microbes when the reprocessing instructions are correctly followed. To support high level disinfection of duodenoscopes, the disinfectant should result in a six-log reduction in the number of microbes at each of several locations on the scope – that is a one million-fold reduction; or a reduction of 99.9999 percent.
The FDA is closely monitoring the possible association between reprocessed duodenoscopes and the transmission of infectious agents, including multidrug-resistant bacterial infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE) such as Klebsiella species and Escherichia coli. If not properly reprocessed, residual body fluids and organic debris may remain in microscopic crevices of the device following an attempted cleaning and high level disinfection. If these residual fluids contain microbial contamination, subsequent patients may be exposed to serious infections. The FDA’s investigation into the possible association between inadequately reprocessed duodenoscopes and patient infections, including the agency’s recommendations for health care facilities, is more fully discussed in its February 2015 Safety Communication.
Olympus sent letters dated March 26, 2015 disclaimer icon to healthcare facilities and other users of the TJF-Q180V outlining the new, validated reprocessing instructions, and will soon be distributing revised user manuals.
The following are key changes to the reprocessing procedure for Olympus’ TJF-Q180V duodenoscope:
• During immersion, raise and lower the elevator three times
• Additional brushing of the forceps elevator recess area ?The revised cleaning procedure requires brushing of the forceps elevator recess with two different-sized brushes. In addition to the brush that is currently used to clean the elevator recess area, the MAJ-1888 brush (or MAJ-1888 equivalent) will be provided for further cleaning of this area. Olympus anticipates shipping the MAJ-1888 brushes to facilities no later than May 8, 2015.
• Additional flushing of forceps elevator recess area
• Additional raising/lowering the forceps elevator
Manual High Level Disinfection:
• Additional manual flushing steps and increased flushing volume of each endoscope channel, as well as the elevator recess area
• Additional raising/lowering the forceps elevator
In addition, FDA has the following recommendations for facilities and staff that use and reprocess the Olympus TJF-Q180V:
• Implement the new manual cleaning and high level disinfection procedures for the Olympus TJF-Q180V duodenoscope in accordance with the manufacturer’s reprocessing instructions
• Implement the new TJF-Q180V high level disinfection procedure immediately. The high level disinfection procedure does not require additional equipment for implementation.
• Implement the new TJF-Q180V manual cleaning procedure as soon as possible. It involves the use of a new, smaller bristle cleaning brush (model MAJ-1888) which Olympus anticipates shipping to facilities no later than May 8, 2015. Continue using the existing cleaning procedure for manual cleaning of the TJF-Q180V until the new brush is available.
•Train appropriate staff on Olympus’ new reprocessing instructions and implement them as soon as possible.
FDA’s recommendations are based on currently available information. If new, important information becomes available, FDA will update its recommendations.
As noted in FDA’s Updated Information for Healthcare Providers Regarding Duodenoscopes issued March 4, 2015, Olympus has a pending 510(k) application for its TJF-Q180V duodenoscope and the company continues to market its device while its application is under review. The removal of its device from the market could lead to an insufficient number of available duodenoscopes to meet the clinical demand in the United State of approximately 500,000 procedures per year.
The FDA is actively engaged with other government agencies, including Centers for Disease Control and Prevention (CDC), and the manufacturers of duodenoscopes used in the United States to identify the causes and risk factors for transmission of infectious agents and develop solutions to further increase the safety margin of reprocessed devices and minimize patient exposure to infectious agents.
The agency will convene a public Advisory Committee Meeting May 14-15, 2015 to seek expert scientific and clinical opinion related to reprocessing of duodenoscopes and other endoscopes, as well as use of automated endoscope reprocessors for duodenoscope reprocessing, based on available scientific information. The committee will make recommendations on: (1) The effectiveness of cleaning, high level disinfection, and sterilization methods; (2) the amount and type of premarket validation data and information needed to support labeling claims and technical instructions; (3) the appropriate use of other risk mitigations, such as surveillance cultures; (4) best practices and guidelines for reprocessing duodenoscopes and endoscopes at user facilities to minimize the transmission of infections; and (5) recommended approaches for ensuring patient safety during ERCP procedures, including a discussion of appropriate patient selection. Recommendations on these issues will assist FDA in minimizing patient exposure to infectious agents that may result from reprocessed duodenoscopes and endoscopes.
The FDA is also working closely with the manufacturers of reusable medical devices such as duodenoscopes to ensure that their reprocessing instructions are adequate to clean and disinfect the devices. The FDA continues to actively monitor this situation and will provide updates as appropriate.